Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 160.43B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 26.87 |
| Forward PE | 16.67 |
| Dividend | 8.52 (2.88%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 460 |
| Average Volume | 578 |
| Open | 296.45 |
| Previous Close | 295.40 |
| Day's Range | 295.60 - 297.95 |
| 52-Week Range | 230.00 - 308.50 |
| Beta | 0.46 |
| RSI | 70.55 |
| Earnings Date | Nov 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m.
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8th annual Evercore ISI HealthCONx Conference at 10:00 a.m.
Amgen Shines As Medical Sector Benefits From Sector Rotation
Despite low relative strength, medical stocks had solid entries in a choppy market.
Notable Thursday Option Activity: TGT, CVX, AMGN
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Target Corp (Symbol: TGT), where a total volume of 46,755 contracts has been traded thu...
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
Dow Movers: AMGN, WMT
In early trading on Thursday, shares of Walmart topped the list of the day's best performing Dow Jones Industrial Average components, trading up 4.4%. Year to date, Walmart registers a 16.3% gain. And...
FDA Grants Full Approval To Amgen's Lung Cancer Drug IMDELLTRA
(RTTNews) - Amgen Inc. (AMGN) announced that the U.S. FDA has granted full approval to IMDELLTRA for adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or...
Amgen's IMDELLTRA Gets Full FDA Approval For Extensive Stage Small Cell Lung Cancer
(RTTNews) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has granted full approval to IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive stage small ce...
Amgen's Imdelltra receives full FDA approval in small cell lung cancer
Amgen (AMGN) Secures Full FDA Approval for IMDELLTRA in Lung Cancer Treatment
Amgen (AMGN) Secures Full FDA Approval for IMDELLTRA in Lung Cancer Treatment
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy Underscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With ...
FDA Grants Full Approval to Amgen's (AMGN) Drug Imdelltra for Lung Cancer Treatment
FDA Grants Full Approval to Amgen's (AMGN) Drug Imdelltra for Lung Cancer Treatment
Ex-Dividend Reminder: NextEra Energy, Amgen and CRH
Looking at the universe of stocks we cover at Dividend Channel, on 11/21/25, NextEra Energy Inc (Symbol: NEE), Amgen Inc (Symbol: AMGN), and CRH plc (Symbol: CRH) will all trade ex-dividend for their ...
Check Out What Whales Are Doing With AMGN
High-rolling investors have positioned themselves bullish on Amgen (NASDAQ: AMGN), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tr...
Noteworthy ETF Inflows: IWB, UBER, C, AMGN
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an appro...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Dow Movers: NKE, AMGN
In early trading on Monday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 1.2%. Year to date, Amgen registers a 30.8% gain. And the w...
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus ...
Amgen EVP Sold $2.32M In Company Stock
Murdo Gordon , EVP at Amgen (NASDAQ: AMGN), executed a substantial insider sell on November 14, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and Ex...
Sell Alert: Rachna Khosla Cashes Out $299K In Amgen Stock
A substantial insider sell was reported on November 14, by Rachna Khosla , SVP at Amgen (NASDAQ: AMGN), based on the recent SEC filing. What Happened: Khosla's recent move involves selling 890 shares...
Amgen (AMGN) Rating Update: Piper Sandler Raises Price Target | AMGN Stock News
Amgen (AMGN) Rating Update: Piper Sandler Raises Price Target | AMGN Stock News
Why Amgen Stock Edged Past the Market on Thursday
The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.
Trade Tracker: Bill Baruch buys more Amgen
Bill Baruch, founder and president at Blue Line Capital, joins CNBC's “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.
Trade Tracker: Bill Baruch buys more Amgen
Bill Baruch, founder and president at Blue Line Capital, joins CNBC’s “Halftime Report” to detail his latest Amgen purchase. The Investment Committee debate the biotech sector.